ECCMID 26th (2016)

Title Content type
The novel orotomide F901318 demonstrates potent in vitro antifungal activity against Lomentospora and Scedosporium species (click for details)
Allometric scaling and the chimpanzee as a surrogate for human pharmacokinetics of CD101, a novel echinocandin (click for details)
Micafungin serum levels in critically ill patients on continous venovenous haemodialysis using high cut-off membranes (CVVHD-HCM) (click for details)
Pharmacokinetics and absolute bioavailability of voriconazole administred through a nasogastric tube with continuous enteral feeding to critically ill ventillated patients (click for details)
Activity against fungi of nonhydrolytic synthesized TiO2 (click for details)
Evaluation of the Sensititre YeastOne colorimetric antifungal panel for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin, adopting the new CLSI clinical breakpoints and epidemiological cutoff values (click for details)
EDTA inhibits Rhizopus oryzae (Rhizopus arrhizus) growth in vitro in blood of diabetic and non-diabetic individuals - is it an option for combined therapy with antifungal agents in the future? (click for details)
Factors correlated to the length of antifungal therapy in a cohort of patients with candidaemia (click for details)
Differences in cytokine levels in diabetic versus non-diabetic mice challenged with Candida albicans and treated with liposomal amphotericin B (click for details)
Subinhibitory concentrations of micafungin exert species-dependent differential effects on Candida and modulate the antifungal activity of human neutrophils against mature biofilms (click for details)


Subscribe to ECCMID 26th (2016)